Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients-Reference-Cited by-同舟云学术

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Published:2021-02-05 Issue:6529 Volume:371 Page:595-602
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Davar Diwakar¹^ORCID,Dzutsev Amiran K.²,McCulloch John A.²^ORCID,Rodrigues Richard R.²³^ORCID,Chauvin Joe-Marc¹^ORCID,Morrison Robert M.¹^ORCID,Deblasio Richelle N.¹,Menna Carmine¹,Ding Quanquan¹,Pagliano Ornella¹^ORCID,Zidi Bochra¹,Zhang Shuowen¹^ORCID,Badger Jonathan H.²^ORCID,Vetizou Marie²^ORCID,Cole Alicia M.²^ORCID,Fernandes Miriam R.²^ORCID,Prescott Stephanie²^ORCID,Costa Raquel G. F.²^ORCID,Balaji Ascharya K.²^ORCID,Morgun Andrey⁴^ORCID,Vujkovic-Cvijin Ivan⁵^ORCID,Wang Hong⁶^ORCID,Borhani Amir A.⁷^ORCID,Schwartz Marc B.⁸^ORCID,Dubner Howard M.⁸^ORCID,Ernst Scarlett J.¹,Rose Amy¹,Najjar Yana G.¹^ORCID,Belkaid Yasmine⁵^ORCID,Kirkwood John M.¹^ORCID,Trinchieri Giorgio²^ORCID,Zarour Hassane M.¹⁹^ORCID

Affiliation:

1. Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.

2. Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

3. Genetics and Microbiome Core, Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.

4. College of Pharmacy, Oregon State University, Corvallis, OR 97331, USA.

5. Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD 20892, USA.

6. Biostatistics Facility, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.

7. Division of Abdominal Imaging, Department of Radiology, University of Pittsburgh, Pittsburgh, PA 15213, USA.

8. Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA 15213, USA.

9. Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15213, USA.

Abstract

New fecal microbiota for cancer patients The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573

Funder

National Cancer Institute

Melanoma Research Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference51 articles.

1. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma

2. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

3. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

4. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

5. Pembrolizumab versus Ipilimumab in Advanced Melanoma

Cited by 715 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative histological description of the intestine in platyfish (Xiphophorus maculatus) and swordtail fish (Xiphophorus helleri);Tissue and Cell;2024-04

2. Translational research in head and neck cancer: Molecular and immunological updates;Auris Nasus Larynx;2024-04

3. Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors;Molecular Therapy: Oncology;2024-03

4. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer;Frontiers in Immunology;2024-02-01

5. Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer;Cell Reports Medicine;2024-02